Literature DB >> 10590146

A heterologous, high-affinity RNA ligand for human immunodeficiency virus Gag protein has RNA packaging activity.

J L Clever1, R A Taplitz, M A Lochrie, B Polisky, T G Parslow.   

Abstract

Retroviral RNA encapsidation depends on the specific binding of Gag proteins to packaging (psi) signals in genomic RNA. We investigated whether an in vitro-selected, high-affinity RNA ligand for the nucleocapsid (NC) portion of the Gag protein from human immunodeficiency virus type 1 (HIV-1) could mediate packaging into HIV-1 virions. We find that this ligand can functionally substitute for one of the Gag-binding elements (termed SL3) in the HIV-1 psi locus to support packaging and viral infectivity in cis. By contrast, this ligand, which fails to dimerize spontaneously in vitro, is unable to replace a different psi element (termed SL1) which is required for both Gag binding and dimerization of the HIV-1 genome. A single point mutation within the ligand that eliminates high-affinity in vitro Gag binding also abolishes its packaging activity at the SL3 position. These results demonstrate that specific binding of Gag or NC protein is a critical determinant of genomic RNA packaging.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10590146      PMCID: PMC111568          DOI: 10.1128/jvi.74.1.541-546.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  A specific RNA structural motif mediates high affinity binding by the HIV-1 nucleocapsid protein (NCp7).

Authors:  P Allen; B Collins; D Brown; Z Hostomsky; L Gold
Journal:  Virology       Date:  1996-11-15       Impact factor: 3.616

2.  A high affinity binding site for the HIV-1 nucleocapsid protein.

Authors:  J A Berglund; B Charpentier; M Rosbash
Journal:  Nucleic Acids Res       Date:  1997-03-01       Impact factor: 16.971

3.  Efficient encapsidation of human immunodeficiency virus type 1 vectors and further characterization of cis elements required for encapsidation.

Authors:  M S McBride; M D Schwartz; A T Panganiban
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  Identification of a binding site for the human immunodeficiency virus type 1 nucleocapsid protein.

Authors:  K Sakaguchi; N Zambrano; E T Baldwin; B A Shapiro; J W Erickson; J G Omichinski; G M Clore; A M Gronenborn; E Appella
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

5.  Specific binding of human immunodeficiency virus type 1 gag polyprotein and nucleocapsid protein to viral RNAs detected by RNA mobility shift assays.

Authors:  R D Berkowitz; J Luban; S P Goff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  A short sequence upstream of the 5' major splice site is important for encapsidation of HIV-1 genomic RNA.

Authors:  H J Kim; K Lee; J J O'Rear
Journal:  Virology       Date:  1994-01       Impact factor: 3.616

7.  Dimerization of human immunodeficiency virus type 1 RNA involves sequences located upstream of the splice donor site.

Authors:  R Marquet; J C Paillart; E Skripkin; C Ehresmann; B Ehresmann
Journal:  Nucleic Acids Res       Date:  1994-01-25       Impact factor: 16.971

8.  Mutant human immunodeficiency virus type 1 genomes with defects in RNA dimerization or encapsidation.

Authors:  J L Clever; T G Parslow
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

9.  Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein.

Authors:  T Dorfman; J Luban; S P Goff; W A Haseltine; H G Göttlinger
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

10.  Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-terminal zinc finger and flanking basic amino acid residues.

Authors:  J Dannull; A Surovoy; G Jung; K Moelling
Journal:  EMBO J       Date:  1994-04-01       Impact factor: 11.598

View more
  17 in total

1.  HIV-2 RNA dimerization is regulated by intramolecular interactions in vitro.

Authors:  Tayyba T Baig; Jean-Marc Lanchy; J Stephen Lodmell
Journal:  RNA       Date:  2007-06-25       Impact factor: 4.942

2.  RNA structure and packaging signals in the 5' leader region of the human immunodeficiency virus type 1 genome.

Authors:  Jared L Clever; Daniel Miranda; Tristram G Parslow
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Deciphering the role of the Gag-Pol ribosomal frameshift signal in HIV-1 RNA genome packaging.

Authors:  Olga A Nikolaitchik; Wei-Shau Hu
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

Review 4.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

Review 5.  Structural determinants and mechanism of HIV-1 genome packaging.

Authors:  Kun Lu; Xiao Heng; Michael F Summers
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

Review 6.  Beyond plasma membrane targeting: role of the MA domain of Gag in retroviral genome encapsidation.

Authors:  Leslie J Parent; Nicole Gudleski
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

7.  Characterization of Rous sarcoma virus Gag particles assembled in vitro.

Authors:  F Yu; S M Joshi; Y M Ma; R L Kingston; M N Simon; V M Vogt
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  Sequences in the 5' and 3' R elements of human immunodeficiency virus type 1 critical for efficient reverse transcription.

Authors:  Y Ohi; J L Clever
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

9.  Functional analysis of the murine sarcoma virus RNA packaging sequence.

Authors:  Elena Izmailova; Anna Aldovini
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 10.  The remarkable frequency of human immunodeficiency virus type 1 genetic recombination.

Authors:  Adewunmi Onafuwa-Nuga; Alice Telesnitsky
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.